Human Oncology & Pathogenesis Program

The Emily Cheng Lab

Share
Back to Top

Research

Emily H. Cheng, MD, PhD
Emily H. Cheng, MD, PhD
Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

The focus of the Cheng laboratory is to elucidate the molecular mechanisms of cell death with an overarching goal of directly translating cell death mechanisms into novel anti-cancer therapeutic strategies that can effectively trigger cancer cell death and enhance anti-cancer immunity.

View Lab Overview

The Cheng Lab

The Cheng Lab

Publications

Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022 Feb 3. doi: 10.1038/s43018-021-00316-3. Epub ahead of print.

Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 Sep 13;39(9):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. PMCID: PMC8440494.

Ren D, Tu H, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.

Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J, Zambetti GP, Hsieh JJD, Cheng EHY. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006 Dec;8(12):1348-58. Epub 2006 Nov 19.

Kim H, Tu H, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009 Nov 13;36(3):487-99. doi: 10.1016/j.molcel.2009.09.030.

View All Publications

People

Emily H. Cheng, MD, PhD

Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

  • Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.
  • MD, Taipei Medical University
  • PhD, Johns Hopkins University School of Medicine
[email protected]
Email Address
646-888-3258
Office Phone

Members

Song Han

Research Assistant

Amrita Mangalvedhekar

Senior Research Scientist

Lunshi Tang

Research Technician

Nobuhiro Tanno

Research Fellow

Kelly Wu

Research Technician

Shaoyuan Yang

Research Fellow

Lab Alumni
Gregory Bean
Gregory Bean

Graduate Research Assistant

Po Chan
Po Chan

Research Technician

Hui-Chen Chen

Research Fellow

Beatrice D'Orsi

Research Fellow

Yafen Huang, PhD
Yafen Huang

Research Fellow

Paul Jeng

Graduate Student

Chung Ping Liao, PhD
Chung Ping Liao

Research Fellow

Yogesh Tengarai Ganesan

Research Technician

Gary Wang
Gary Wang

Graduate Research Assistant

Akane Yamauchi

Research Fellow

Kota Ishizawa

Research Fellow

Kai Xi Lin

Research Technician

Allison Moyer
Shriram Ramani

Research Technician

Danielle Richards

Program Assistant

Sonali Sinha
Swathi Suresh

Graduate Research Assistant

Kosuke Tanaka
Yuchen Xie
Yuchen Xie

Data Scientist at Audible, Inc., Newark, NJ

Wudan Yan

Graduate Student

Ju Zhou
Lab Affiliations

Achievements

  • Distinguished Investigator Award, Washington University School of Medicine (2010)
  • Searle Scholar Award (2005)
  • Howard Temin Award, National Cancer Institute (2003)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Emily H. Cheng discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures